News
News Center
The "Tianjin Municipal Biopharmaceutical Industry Development Special Plan for the 14th Five-Year Period" has been released, with a focus on building the Bincheng Biopharmaceutical Industry Cluster Core Area.
2021-11-22
Recently, the "Tianjin Municipal Biopharmaceutical Industry Development Special Plan for the 14th Five-Year Period" (hereafter referred to as the "Special Plan") was unveiled. The Special Plan outlines that, aligned with Tianjin's dual-city development strategy centered on "Jincheng" and "Bincheng," the city will focus on leveraging the pivotal roles of leading enterprises and institutions, while strengthening the cluster-building capabilities of specialized industrial parks. Key initiatives include developing Bincheng into a core hub for biopharmaceutical industry clusters, and designating the central two districts of Jincheng, the four districts surrounding the city center, and the three outermost regions as priority areas for biopharmaceutical growth. This approach aims to establish a new spatial layout for the biopharmaceutical industry characterized by "leading enterprises driving growth, park-based support, cross-regional collaboration, and comprehensive regional expansion."
The "Special Plan" proposes:
(II) Building Five Distinctive Industry Clusters
3. Biopharmaceutical Industry Cluster: Following the approach of "proactive planning, large-scale translation, scalable application, and intelligent enhancement," we will accelerate the widespread adoption and scaled development of gene technology applications. We will also proactively position ourselves in cutting-edge areas such as antibody drugs, antibody-drug conjugates, novel structured proteins and peptide-based therapeutics, nucleic acid medicines, and system-targeted biologics. Additionally, we’ll drive innovation in next-generation vaccines—including cancer, HIV, and COVID-19 vaccines—as well as breakthrough treatments for major diseases like cardiovascular and cerebrovascular disorders, neurodegenerative conditions, diabetes, autoimmune illnesses, hematological disorders, and other critical health challenges. Developing and cultivating stem cell-based organ regeneration drugs, as well as novel monoclonal antibody therapies such as bispecific antibodies and antibody-drug conjugates. Support the introduction and production of high-end generic drugs, first-to-market generics, and more, while enhancing the quality standards of gene- and regenerative medicine-based generic products.
(III) Implement Eight Key Projects
1. Implementing the Dual Enhancement Project for Scale and Quality in the Biopharmaceutical Industry
(2) Focusing intensively on building a specialized biopharmaceutical industrial park: We are fully committed to developing several specialized biopharmaceutical industrial parks, including the Binhai New Area Cell Valley and Bio-Manufacturing Valley, the Jinghai China-Japan (Tianjin) Health Industry Development Cooperation Demonstration Zone, and the Beichen Beijing-Tianjin Pharmaceutical Valley, while strengthening a group of cutting-edge biopharmaceutical manufacturing hubs. Enhance the concentration and attractiveness of enterprises in the biopharmaceutical industrial park, enabling it to better attract innovative breakthroughs and industry projects. Leveraging the strengths of Tianjin University of Traditional Chinese Medicine, we will establish a TCM-focused industrial park with distinctive features. The park will actively recruit major innovation-driven pharmaceutical and medical device projects that boast high visibility, strong market influence, and excellent economic returns, while also drawing renowned domestic and international pharmaceutical companies and cutting-edge medical device firms to set up their headquarters, R&D centers, and production facilities in Tianjin.
3. Implementing the Industrial Service System Construction Project
(2) Promote the development of platforms for the application and commercialization of key biopharmaceutical products: Foster diverse intermediary service organizations dedicated to translating biopharmaceutical research into practical applications, and enhance the specialized service capabilities for technology transfer in this field. Establish standardized, independent third-party service systems covering areas such as genetic testing, gene data interpretation, and traditional Chinese medicine analysis, thereby accelerating the adoption and integration of cutting-edge detection and diagnostic technologies across various segments of the biotech industry. Develop specialized service platforms for gene therapy, cell therapy, immunotherapy, and other cutting-edge treatments that align with international standards, accelerating the translation and adoption of innovative therapeutic technologies. Supporting high-end professional service institutions specializing in gene synthesis, gene editing, and other advanced technologies, while promoting specialized services for innovative, cross-cutting technologies.
V. Assurance Measures
(III) Accelerate Policy Innovation: Take the lead in piloting national biomedical industry policies, establish wholly foreign-owned hospitals, shorten the approval process for importing medical devices and pharmaceuticals, and ease restrictions on the working hours of foreign physicians. Relaxing market access for cutting-edge medical technologies like stem cells, and introducing groundbreaking policy measures such as establishing foreign-invested specialized health insurance institutions. Explore and implement "risk-based classification and access categorization" management for cell therapy within the Tianjin Free Trade Zone, allowing relevant policies to be rolled out in the China-Japan (Tianjin) Health Industry Development Cooperation Demonstration Zone. Additionally, align with evolving industry trends by promptly introducing follow-up measures tailored to the biopharmaceutical sector, ensuring policy continuity and stability.
Reprint Notice: This article is reprinted from the official website of the Tianjin Municipal Bureau of Industry and Information Technology. If there is any infringement, please contact us for removal.
Related News
Here is the title—h1 placeholder text
Copyright © Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.
Powered by: 300.cn SEO | Privacy Policy